Harvard Bioscience's Q2 Revenue Rises 11%; Raises FY26 Growth Outlook
Harvard Bioscience (HBIO) reported Q2 revenue of $22.7 million, up 11% year over year, with gross profit $12.6 million and gross margin 55.6%. Adjusted EBITDA rose to $1.7 million. The company raised FY2026 revenue growth guidance to 3%-5% and expects Q3 2026 revenue of $21.0 million to $22.6 million.
How this was made
The 30-second read
Why it matters
The key tradable items are the FY26 revenue growth guidance increase to 3%-5%, the implied FY26 revenue range, and the Q3 2026 revenue and adjusted margin/EBITDA ranges.
Market read
This is a company-specific earnings and guidance update with enough detail (revenue, margins, EBITDA, and ranges) to adjust near-term expectations and risk for HBIO.
What to watch
Net loss remains sizable, and gross margin is slightly lower year over year (55.6% vs 56.4%), so traders may focus on whether adjusted EBITDA growth offsets margin pressure.
Background
HBIO is a provider of technologies and products supporting life science research, with growth tied to telemetry and CMT (cellular and molecular) product lines.
Ticker impact
Harvard Bioscience reported Q2 revenue of $22.7M, up 11%, and raised FY26 revenue growth guidance to 3%-5%.
Bias modestly upward, with follow-through dependent on whether Q3 revenue and adjusted EBITDA land within the guided ranges.
The article discloses a concrete FY26 guidance increase (2%-4% to 3%-5%) and provides Q3 revenue and margin/EBITDA ranges, which are actionable for positioning. However, the magnitude is moderate and the company still reports a net loss, limiting conviction.
Market effects
Signals continued demand strength in life-science research tools, potentially supportive for small-cap peers with similar CMT/telemetry exposure.
No specific regional demand detail beyond a mention of China momentum, so limited broader regional read-through.
Limited global macro linkage; primarily company-specific guidance and product-demand commentary.
Counterpoint
Raised guidance could still be consistent with a low base and may not translate into sustained profitability if gross margin compresses toward the low end of the range.
Key entities
- public_companyHarvard Bioscience, Inc.
Announced Q2 results and raised FY26 revenue growth guidance; provided Q3 2026 revenue and profitability ranges.
